Discovery

Major research discoveries, ususally linked to a high profile publication.

The Inflammasome Lab is thrilled to have contributed to the development NLRP3 inhibitors, now under translation to the clinic by Roche for treatment of inflammatory and neurodegenerative diseases.

Read more

The Inflammasome lab is thrilled that NLRP3 inflammasome inhibitors are now in Phase II in clinical trials with Inflazome.

Read more

Stefan Emming and Kate Schroder from the Inflammasome Lab have published a review in Science magazine this month on how "Multiple DNA sensors (TLR9, hnRNP-A2B1, cGAS, and AIM2) in different cellular compartments may allow

Read more

The Inflammasome Lab have defined the molecular target of MCC950, revealing the mechanism by which this potent and specific small-molecule inhibitor inhibits the NLRP3 inflammasome.  

Read more

The Inflammasome Lab have discovered a new pathway for host defence against cytosolic Gram-negative bacteria, revealing unexpected links between pyroptosis and NETosis.

Read more

Here the Inflammasome Lab reveal that Salmonella evades immune response by subverting the NLRP3 and NLRC4 inflammasome in macrophages.

Read more

The Inflammasome Lab have discovered a new pathway for host defence against cytosolic Gram-negative bacteria, revealing unexpected links between pyroptosis and NETosis.

Read more

New research from Inflammasome Lab reveals trafficking mechanisms driving the unconventional secretion of mature interleukin-1β in non-pyroptotic and pyroptotic myeloid cells, and functions for caspase-1 and Gasdermin-D therein.

Read more

The lab celebrated new paper acceptances with a pub crawl of Brisbane's finest establishments in West End on Friday. Congratulations to everyone in the Inflammasome Lab, and to our wonderful overseas collaborators!

Read more

The Inflammasome Lab is thrilled to have our recent research featured in the Journal of Experimental Medicine special collection.  

Read more

Pages